PortalPublikationenEffect of oral β-blocker on short and long-term mortality in...

Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study

Standard

Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. / Noveanu, Markus; Breidthardt, Tobias; Reichlin, Tobias; Gayat, Etienne; Potocki, Mihael; Pargger, Hans; Heise, Antje; Meissner, Julia; Twerenbold, Raphael; Muravitskaya, Natalia; Mebazaa, Alexandre; Mueller, Christian.

in: CRIT CARE, Jahrgang 14, Nr. 6, 2010, S. R198.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Noveanu, M, Breidthardt, T, Reichlin, T, Gayat, E, Potocki, M, Pargger, H, Heise, A, Meissner, J, Twerenbold, R, Muravitskaya, N, Mebazaa, A & Mueller, C 2010, 'Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study', CRIT CARE, Jg. 14, Nr. 6, S. R198. https://doi.org/10.1186/cc9317

APA

Noveanu, M., Breidthardt, T., Reichlin, T., Gayat, E., Potocki, M., Pargger, H., Heise, A., Meissner, J., Twerenbold, R., Muravitskaya, N., Mebazaa, A., & Mueller, C. (2010). Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. CRIT CARE, 14(6), R198. https://doi.org/10.1186/cc9317

Vancouver

Noveanu M, Breidthardt T, Reichlin T, Gayat E, Potocki M, Pargger H et al. Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. CRIT CARE. 2010;14(6):R198. https://doi.org/10.1186/cc9317

Bibtex

@article{c162d7cf33c84716ac7bc38bb7c15b11,
title = "Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study",
abstract = "INTRODUCTION: Acute respiratory failure (ARF) is responsible for about one-third of intensive care unit (ICU) admissions and is associated with adverse outcomes. Predictors of short- and long-term outcomes in unselected ICU-patients with ARF are ill-defined. The purpose of this analysis was to determine predictors of in-hospital and one-year mortality and assess the effects of oral beta-blockers in unselected ICU patients with ARF included in the BASEL-II-ICU study.METHODS: The BASEL II-ICU study was a prospective, multicenter, randomized, single-blinded, controlled trial of 314 (mean age 70 (62 to 79) years) ICU patients with ARF evaluating impact of a B-type natriuretic peptide- (BNP) guided management strategy on short-term outcomes.RESULTS: In-hospital mortality was 16% (51 patients) and one-year mortality 41% (128 patients). Multivariate analysis assessed that oral beta-blockers at admission were associated with a lower risk of both in-hospital (HR 0.33 (0.14 to 0.74) P = 0.007) and one-year mortality (HR 0.29 (0.16 to 0.51) P = 0.0003). Kaplan-Meier analysis confirmed the lower mortality in ARF patients when admitted with oral beta-blocker and further shows that the beneficial effect of oral beta-blockers at admission holds true in the two subgroups of patients with ARF related to cardiac or non-cardiac causes. Kaplan-Meier analysis also shows that administration of oral beta-blockers before hospital discharge gives striking additional beneficial effects on one-year mortality.CONCLUSIONS: Established beta-blocker therapy appears to be associated with a reduced mortality in ICU patients with acute respiratory failure. Cessation of established therapy appears to be hazardous. Initiation of therapy prior to discharge appears to confer benefit. This finding was seen regardless of the cardiac or non-cardiac etiology of respiratory failure.TRIAL REGISTRATION: clinicalTrials.gov Identifier: NCT00130559.",
keywords = "Acute Disease, Administration, Oral, Adrenergic beta-Antagonists/administration & dosage, Aged, Female, Follow-Up Studies, Hospital Mortality/trends, Humans, Intensive Care Units/trends, Male, Middle Aged, Prospective Studies, Respiratory Insufficiency/drug therapy, Single-Blind Method, Survival Rate/trends, Switzerland/epidemiology, Time Factors, Treatment Outcome",
author = "Markus Noveanu and Tobias Breidthardt and Tobias Reichlin and Etienne Gayat and Mihael Potocki and Hans Pargger and Antje Heise and Julia Meissner and Raphael Twerenbold and Natalia Muravitskaya and Alexandre Mebazaa and Christian Mueller",
year = "2010",
doi = "10.1186/cc9317",
language = "English",
volume = "14",
pages = "R198",
journal = "CRIT CARE",
issn = "1364-8535",
publisher = "Springer Science + Business Media",
number = "6",

}

RIS

TY - JOUR

T1 - Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study

AU - Noveanu, Markus

AU - Breidthardt, Tobias

AU - Reichlin, Tobias

AU - Gayat, Etienne

AU - Potocki, Mihael

AU - Pargger, Hans

AU - Heise, Antje

AU - Meissner, Julia

AU - Twerenbold, Raphael

AU - Muravitskaya, Natalia

AU - Mebazaa, Alexandre

AU - Mueller, Christian

PY - 2010

Y1 - 2010

N2 - INTRODUCTION: Acute respiratory failure (ARF) is responsible for about one-third of intensive care unit (ICU) admissions and is associated with adverse outcomes. Predictors of short- and long-term outcomes in unselected ICU-patients with ARF are ill-defined. The purpose of this analysis was to determine predictors of in-hospital and one-year mortality and assess the effects of oral beta-blockers in unselected ICU patients with ARF included in the BASEL-II-ICU study.METHODS: The BASEL II-ICU study was a prospective, multicenter, randomized, single-blinded, controlled trial of 314 (mean age 70 (62 to 79) years) ICU patients with ARF evaluating impact of a B-type natriuretic peptide- (BNP) guided management strategy on short-term outcomes.RESULTS: In-hospital mortality was 16% (51 patients) and one-year mortality 41% (128 patients). Multivariate analysis assessed that oral beta-blockers at admission were associated with a lower risk of both in-hospital (HR 0.33 (0.14 to 0.74) P = 0.007) and one-year mortality (HR 0.29 (0.16 to 0.51) P = 0.0003). Kaplan-Meier analysis confirmed the lower mortality in ARF patients when admitted with oral beta-blocker and further shows that the beneficial effect of oral beta-blockers at admission holds true in the two subgroups of patients with ARF related to cardiac or non-cardiac causes. Kaplan-Meier analysis also shows that administration of oral beta-blockers before hospital discharge gives striking additional beneficial effects on one-year mortality.CONCLUSIONS: Established beta-blocker therapy appears to be associated with a reduced mortality in ICU patients with acute respiratory failure. Cessation of established therapy appears to be hazardous. Initiation of therapy prior to discharge appears to confer benefit. This finding was seen regardless of the cardiac or non-cardiac etiology of respiratory failure.TRIAL REGISTRATION: clinicalTrials.gov Identifier: NCT00130559.

AB - INTRODUCTION: Acute respiratory failure (ARF) is responsible for about one-third of intensive care unit (ICU) admissions and is associated with adverse outcomes. Predictors of short- and long-term outcomes in unselected ICU-patients with ARF are ill-defined. The purpose of this analysis was to determine predictors of in-hospital and one-year mortality and assess the effects of oral beta-blockers in unselected ICU patients with ARF included in the BASEL-II-ICU study.METHODS: The BASEL II-ICU study was a prospective, multicenter, randomized, single-blinded, controlled trial of 314 (mean age 70 (62 to 79) years) ICU patients with ARF evaluating impact of a B-type natriuretic peptide- (BNP) guided management strategy on short-term outcomes.RESULTS: In-hospital mortality was 16% (51 patients) and one-year mortality 41% (128 patients). Multivariate analysis assessed that oral beta-blockers at admission were associated with a lower risk of both in-hospital (HR 0.33 (0.14 to 0.74) P = 0.007) and one-year mortality (HR 0.29 (0.16 to 0.51) P = 0.0003). Kaplan-Meier analysis confirmed the lower mortality in ARF patients when admitted with oral beta-blocker and further shows that the beneficial effect of oral beta-blockers at admission holds true in the two subgroups of patients with ARF related to cardiac or non-cardiac causes. Kaplan-Meier analysis also shows that administration of oral beta-blockers before hospital discharge gives striking additional beneficial effects on one-year mortality.CONCLUSIONS: Established beta-blocker therapy appears to be associated with a reduced mortality in ICU patients with acute respiratory failure. Cessation of established therapy appears to be hazardous. Initiation of therapy prior to discharge appears to confer benefit. This finding was seen regardless of the cardiac or non-cardiac etiology of respiratory failure.TRIAL REGISTRATION: clinicalTrials.gov Identifier: NCT00130559.

KW - Acute Disease

KW - Administration, Oral

KW - Adrenergic beta-Antagonists/administration & dosage

KW - Aged

KW - Female

KW - Follow-Up Studies

KW - Hospital Mortality/trends

KW - Humans

KW - Intensive Care Units/trends

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Respiratory Insufficiency/drug therapy

KW - Single-Blind Method

KW - Survival Rate/trends

KW - Switzerland/epidemiology

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1186/cc9317

DO - 10.1186/cc9317

M3 - SCORING: Journal article

C2 - 21047406

VL - 14

SP - R198

JO - CRIT CARE

JF - CRIT CARE

SN - 1364-8535

IS - 6

ER -